Cargando…

Serum Fibroblast Growth Factor 21 and New-Onset Metabolic Syndrome: KoGES-ARIRANG Study

PURPOSE: Fibroblast growth factor 21 (FGF21) is a crucial metabolic regulator, with multiple favorable effects on glucose homeostasis and lipid metabolism. Since serum FGF21 level has been implicated as a potential marker for the early identification of metabolic syndrome (MetS), we investigated the...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Jung Ran, Kim, Jang-Young, Park, Il Hwan, Huh, Ji Hye, Kim, Ki Woo, Cha, Seung-Kuy, Park, Kyu-Sang, Sohn, Joon Hyung, Park, Jong Taek, Koh, Sang Baek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Yonsei University College of Medicine 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5823832/
https://www.ncbi.nlm.nih.gov/pubmed/29436198
http://dx.doi.org/10.3349/ymj.2018.59.2.287
_version_ 1783301935389999104
author Choi, Jung Ran
Kim, Jang-Young
Park, Il Hwan
Huh, Ji Hye
Kim, Ki Woo
Cha, Seung-Kuy
Park, Kyu-Sang
Sohn, Joon Hyung
Park, Jong Taek
Koh, Sang Baek
author_facet Choi, Jung Ran
Kim, Jang-Young
Park, Il Hwan
Huh, Ji Hye
Kim, Ki Woo
Cha, Seung-Kuy
Park, Kyu-Sang
Sohn, Joon Hyung
Park, Jong Taek
Koh, Sang Baek
author_sort Choi, Jung Ran
collection PubMed
description PURPOSE: Fibroblast growth factor 21 (FGF21) is a crucial metabolic regulator, with multiple favorable effects on glucose homeostasis and lipid metabolism. Since serum FGF21 level has been implicated as a potential marker for the early identification of metabolic syndrome (MetS), we investigated the association between serum FGF21 level and the development of MetS in a population-based prospective study. MATERIALS AND METHODS: We conducted a prospective study of 221 randomly sampled adults without MetS from a general population-based cohort study who were examined from 2005–2008 (baseline) and from 2008–2011 (follow-up). Baseline serum FGF21 levels were analyzed using enzyme-linked immunosorbent assay. RESULTS: During the average 2.8-year follow-up period, 82 participants (36.6%) developed new-onset MetS. Serum FGF21 levels were significantly higher in patients with new-onset MetS than in those without MetS (209.56±226.80 vs. 110.09±81.10, p<0.01). In multivariate adjusted models, the odds for MetS development were greater in patients with serum FGF21 levels in the highest quartile, compared to those in the lowest quartile (3.84, 95% confidence interval: 1.59–9.28). CONCLUSION: Serum FGF21 level was an independent predictor for new-onset MetS in a population-based prospective study.
format Online
Article
Text
id pubmed-5823832
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Yonsei University College of Medicine
record_format MEDLINE/PubMed
spelling pubmed-58238322018-03-01 Serum Fibroblast Growth Factor 21 and New-Onset Metabolic Syndrome: KoGES-ARIRANG Study Choi, Jung Ran Kim, Jang-Young Park, Il Hwan Huh, Ji Hye Kim, Ki Woo Cha, Seung-Kuy Park, Kyu-Sang Sohn, Joon Hyung Park, Jong Taek Koh, Sang Baek Yonsei Med J Original Article PURPOSE: Fibroblast growth factor 21 (FGF21) is a crucial metabolic regulator, with multiple favorable effects on glucose homeostasis and lipid metabolism. Since serum FGF21 level has been implicated as a potential marker for the early identification of metabolic syndrome (MetS), we investigated the association between serum FGF21 level and the development of MetS in a population-based prospective study. MATERIALS AND METHODS: We conducted a prospective study of 221 randomly sampled adults without MetS from a general population-based cohort study who were examined from 2005–2008 (baseline) and from 2008–2011 (follow-up). Baseline serum FGF21 levels were analyzed using enzyme-linked immunosorbent assay. RESULTS: During the average 2.8-year follow-up period, 82 participants (36.6%) developed new-onset MetS. Serum FGF21 levels were significantly higher in patients with new-onset MetS than in those without MetS (209.56±226.80 vs. 110.09±81.10, p<0.01). In multivariate adjusted models, the odds for MetS development were greater in patients with serum FGF21 levels in the highest quartile, compared to those in the lowest quartile (3.84, 95% confidence interval: 1.59–9.28). CONCLUSION: Serum FGF21 level was an independent predictor for new-onset MetS in a population-based prospective study. Yonsei University College of Medicine 2018-03-01 2018-02-05 /pmc/articles/PMC5823832/ /pubmed/29436198 http://dx.doi.org/10.3349/ymj.2018.59.2.287 Text en © Copyright: Yonsei University College of Medicine 2018 http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Choi, Jung Ran
Kim, Jang-Young
Park, Il Hwan
Huh, Ji Hye
Kim, Ki Woo
Cha, Seung-Kuy
Park, Kyu-Sang
Sohn, Joon Hyung
Park, Jong Taek
Koh, Sang Baek
Serum Fibroblast Growth Factor 21 and New-Onset Metabolic Syndrome: KoGES-ARIRANG Study
title Serum Fibroblast Growth Factor 21 and New-Onset Metabolic Syndrome: KoGES-ARIRANG Study
title_full Serum Fibroblast Growth Factor 21 and New-Onset Metabolic Syndrome: KoGES-ARIRANG Study
title_fullStr Serum Fibroblast Growth Factor 21 and New-Onset Metabolic Syndrome: KoGES-ARIRANG Study
title_full_unstemmed Serum Fibroblast Growth Factor 21 and New-Onset Metabolic Syndrome: KoGES-ARIRANG Study
title_short Serum Fibroblast Growth Factor 21 and New-Onset Metabolic Syndrome: KoGES-ARIRANG Study
title_sort serum fibroblast growth factor 21 and new-onset metabolic syndrome: koges-arirang study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5823832/
https://www.ncbi.nlm.nih.gov/pubmed/29436198
http://dx.doi.org/10.3349/ymj.2018.59.2.287
work_keys_str_mv AT choijungran serumfibroblastgrowthfactor21andnewonsetmetabolicsyndromekogesarirangstudy
AT kimjangyoung serumfibroblastgrowthfactor21andnewonsetmetabolicsyndromekogesarirangstudy
AT parkilhwan serumfibroblastgrowthfactor21andnewonsetmetabolicsyndromekogesarirangstudy
AT huhjihye serumfibroblastgrowthfactor21andnewonsetmetabolicsyndromekogesarirangstudy
AT kimkiwoo serumfibroblastgrowthfactor21andnewonsetmetabolicsyndromekogesarirangstudy
AT chaseungkuy serumfibroblastgrowthfactor21andnewonsetmetabolicsyndromekogesarirangstudy
AT parkkyusang serumfibroblastgrowthfactor21andnewonsetmetabolicsyndromekogesarirangstudy
AT sohnjoonhyung serumfibroblastgrowthfactor21andnewonsetmetabolicsyndromekogesarirangstudy
AT parkjongtaek serumfibroblastgrowthfactor21andnewonsetmetabolicsyndromekogesarirangstudy
AT kohsangbaek serumfibroblastgrowthfactor21andnewonsetmetabolicsyndromekogesarirangstudy